The combination of GLP-1 receptor agonists and SGLT-2 inhibitors reduces the risk of major adverse liver outcomes by 39% compared to GLP-1 receptor agonists alone and by 43% compared to SGLT-2 inhibitors alone. Additionally, the combination therapy lowers the risk of major adverse cardiovascular events by 35% and 20%, respectively.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
